Navigation Links
VIVUS to Present at the 10th Annual Needham Healthcare Conference
Date:3/29/2011

MOUNTAIN VIEW, Calif., March 29, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 10th Annual Needham Healthcare Conference.  

The VIVUS presentation will take place at the Palace Hotel in New York, New York on Tuesday, April 5, 2011 at 2:00 p.m. ET.  A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com. CONTACT:   VIVUS, Inc.Investor Relations: The Trout GroupTimothy E. Morris

Brian KorbChief Financial Officer

bkorb@troutgroup.com650-934-5200

646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
2. VIVUS to Present at Four Upcoming Investor Conferences
3. VIVUS to Present at Two Upcoming Investor Conferences
4. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
5. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
6. VIVUS to Present at Four Upcoming Healthcare Conferences
7. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
8. VIVUS to Present at the Needham and Company Life Sciences Conference
9. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
10. VIVUS Reports First Quarter 2009 Financial Results and Highlights
11. Chimerix to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website that ... used solely in scientific experiments, is currently celebrating its ... business, Maxim Peptide, which was created by the founders ... and updated website that now features a special deals ... updated with fascinating articles about peptide research, including a ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its new ... GLOBAL MARKETS , the global market for digital polymerase ... 2013. This is estimated to grow to $490 billion ... (CAGR) of 28.6%. , New digital PCR technology has ... the broader PCR field. The opportunities presented by this ...
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
... Executive Chairman and CFO Assume Leadership Responsibilities; CEO Search ... ... Calif., Jan. 30 Genelabs,Technologies, Inc. (Nasdaq: GNLB ) announced ... Officer and Director of the,company, effective January 29, 2008. Irene A. ...
... BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864), ... BioPharma Corp.,announces that at the Company,s Annual General ... of the resolutions presented by,management, appointing KPMG LLP ... Jack Kay, Slawomir Majewski, and Gordon Lickrish as,directors, ...
... Fla., Jan. 30 John Wagner, M.D., recognized as,a ... transplantation, has joined,the team at CORD:USE Cord Blood Bank. ... stem cell biology will provide a,significant contribution to CORD:USE., ... a member of our,distinguished team," says Edward Guindi, M.D., ...
Cached Biology Technology:Genelabs Technologies, Inc. Announces Resignation of President and CEO 2Helix BioPharma shareholders vote in favour of management 2CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 2CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 3
(Date:7/11/2014)... division of the striatum is also involved in ... of substance P in the striatal marginal division ... his team, College of Biophotonics, South China Normal ... P receptor, neurokinin 1 was highly expressed in ... rats. Unilateral or bilateral injection of an antisense ...
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
(Date:7/11/2014)... toxins to study the proteins that let nerve cells ... have stumbled upon a biological tactic that may offer ... in a safe and environmentally responsible way. , ... for one species and harmless for a closely related ... pests without harming beneficial species like bees. A summary ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... The International Rett Syndrome Foundation (IRSF) has named ... the 7th World Congress for Rett Syndrome. ... meetings targeting researchers, clinicians, medical professionals and families ... Family Education Conference and a Science Symposium co-chaired ...
... Conservation Science and the Department of Fish and Game have ... on bird species of greatest concern. This first-of-its-kind study prioritizes ... conservation measures in California. The study was published this week ... exciting about the study is that our unique approach is ...
... thousands of cargo containers from around the world pass through ... some that are not so welcome: drugs, explosives, chemical, biological, ... The possible concealment of such items in containers led lawmakers ... cargo containersthousands per port per day. The Department of ...
Cached Biology News:New study will help protect vulnerable birds from impacts of climate change 2When your ship comes in 2When your ship comes in 3
... products ATP-Free using Mo Bio luciferase assay. Mo ... service that will allow you to certify your ... and enable you to deliver them to your ... ATP detection limit is 3.5 x 10-12 /l, ...
... provides a comprehensive microarray service for ... embedded within non-coding RNAs (ncRNAs) using ... probe design, which enables highly sensitive ... RNAs (1). This comprehensive service includes ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... For knockdown of all human, mouse, ... , Genomewide, predesigned siRNAs for ... , Ready-to-use, convenient matching solutions ... Cost-effective RNAi and downstream ...
Biology Products: